Welcome to our dedicated page for XOMA Royalty news (Ticker: XOMAO), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty stock.
XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (Nasdaq: XOMAO) are linked to XOMA Royalty’s preferred stock and to a business model centered on biotechnology royalty aggregation. The XOMAO news feed captures company announcements that describe how XOMA Royalty acquires future economic rights to therapeutic candidates licensed to pharmaceutical and biotechnology partners, and how this activity relates to its preferred stock capital structure.
In its press releases, XOMA Royalty highlights transactions that shape its royalty and milestone portfolio. News items include strategic royalty sharing agreements, such as the amendment of a long-standing collaboration with Takeda involving mezagitamab and a basket of development-stage assets, as well as the acquisition of milestone and royalty interests tied to programs being developed by companies like Neurocrine Biosciences, Mirum Pharmaceuticals, Oak Hill Bio, and Recursion Pharmaceuticals. These disclosures explain how XOMA Royalty seeks to expand and diversify its economic exposure across multiple therapeutic areas and stages of development.
The news flow also covers corporate acquisitions that add new partnered pipelines and potential royalty streams. Recent announcements describe completed transactions to acquire HilleVax, LAVA Therapeutics, and Mural Oncology, where XOMA Royalty used cash consideration and contingent value rights in tender offers or schemes of arrangement. These updates detail the transaction structures, tender conditions, and subsequent delisting of the acquired companies’ shares from Nasdaq.
For holders and prospective investors in XOMAO, the news page provides insight into preferred stock dividends authorized by XOMA Royalty’s Board of Directors for the 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares, along with timing and per-share dividend amounts. Financial results releases further describe royalty and milestone receipts from commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, as well as business development activities that may influence future royalty flows.
By following XOMAO-related news, readers can track XOMA Royalty’s reported progress in building its portfolio of royalty and milestone rights, understand the terms of key transactions, and see how the company describes its role in providing non-dilutive, non-recourse funding to biotech counterparties. This context can be useful for those monitoring developments that may affect XOMA Royalty’s preferred stock and overall royalty aggregation strategy.
XOMA Royalty (NASDAQ: XOMA) has entered into a definitive merger agreement to acquire HilleVax (NASDAQ: HLVX) in a deal that values HilleVax shares at $1.95 in cash per share plus a contingent value right (CVR).
The CVR includes potential additional payments from: (1) excess cash above $102.95 million, (2) 90-100% of savings from Boston office lease obligations, and (3) 90% of proceeds from any norovirus vaccine program sales within specific timeframes. The deal has secured support from 22.9% of HilleVax stockholders, including officers and directors.
XOMA Royalty will commence a tender offer by August 18, 2025, with the acquisition expected to close in September 2025. The deal requires a majority of HilleVax shares to be tendered and maintaining a minimum cash balance at closing.
XOMA Royalty (NASDAQ:XOMA) has announced a definitive merger agreement to acquire Turnstone Biologics (NASDAQ-CM:TSBX). Under the terms of the agreement, XOMA will pay $0.34 in cash per share plus one non-transferable contingent value right (CVR) for each Turnstone share.
The acquisition will proceed through a tender offer starting by July 11, 2025, requiring a majority of outstanding shares to be tendered and meeting certain conditions including minimum cash balance requirements. Approximately 25.2% of Turnstone stockholders have already agreed to tender their shares. The merger is expected to close in August 2025.
XOMA Royalty Corporation (NASDAQ: XOMA) has acquired BioInvent International's future royalty and milestone rights for mezagitamab (TAK-079) in a deal worth up to $30 million. The transaction includes $20 million paid at closing and an additional $10 million contingent upon mezagitamab receiving FDA marketing approval for IgA nephropathy.
With this acquisition and its existing entitlements, XOMA will receive up to $16.25 million in milestones from Takeda and mid-single digit royalties on future mezagitamab commercial sales. Takeda is currently conducting a Phase 3 clinical trial for mezagitamab in immune thrombocytopenia (ITP) patients. The drug is a fully human IgG1 monoclonal antibody targeting CD38-expressing cells, with potential to become best-in-class in its category.
XOMA Royalty Corporation (NASDAQ: XOMA) announced its participation in two upcoming investor conferences. At the H.C. Wainwright 1st Annual Royalty Company Virtual Conference on May 13, 2025, CEO Owen Hughes and CIO Brad Sitko will lead multiple sessions. Hughes will participate in a fireside chat at 2:30 PM ET and join a panel on royalty model pros and cons at 4:00 PM ET. Sitko will discuss development-stage companies and royalty platforms at 5:00 PM ET.
Additionally, XOMA's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025. The presentations will be accessible through XOMA's investor relations website.
XOMA Royalty (NASDAQ: XOMA) has successfully completed the sale of all five pipeline assets acquired from its Kinnate Biopharma acquisition. The deal could yield up to $270 million in upfront and milestone payments, plus royalties ranging from low single digits to mid-teens on commercial sales.
The transaction follows XOMA's acquisition of Kinnate Biopharma on April 3, 2024. Under the agreement, holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all payments received by XOMA Royalty before April 2, 2029, including upfront payments, milestones, and royalties related to these assets.
XOMA Royalty (NASDAQ: XOMA), a biotech royalty aggregator, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference. Chief Investment Officer Brad Sitko will deliver a presentation on Wednesday, April 9, 2025, at 10:30 AM PT.
The presentation will be accessible through a dedicated link and the investor relations section of XOMA's website. Interested parties can access the replay, which will remain available for 90 days following the event.
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividend payments for its preferred stockholders. The company's Board of Directors has authorized dividends for two series of preferred stock:
- Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share, with each depositary share representing 1/1000 of a preferred share
Both dividend payments are scheduled for April 15, 2025, with a record date of April 3, 2025.
XOMA Royalty reported its Q4 and full year 2024 financial results, highlighting significant portfolio expansion and business achievements. The company doubled its royalty and milestone portfolio to over 120 assets through five transactions in 2024, including two whole company acquisitions.
Key financial metrics include:
- Q4 cash receipts: $4.0 million
- Full-year cash receipts: $46.3 million
- Q4 total income: $8.7 million
- Full-year total income: $28.5 million
- Year-end cash position: $106.4 million
Notable developments include FDA approvals for Day One's OJEMDA™ and Zevra's MIPLYFFA™. The company deployed $65 million to acquire new milestone and royalty assets and paid $5.5 million in dividends. However, XOMA recorded a net loss of $4.0 million in Q4 and $13.8 million for the full year 2024, primarily due to $30.9 million in non-cash credit losses on purchased receivables.